Clinical trials · Massachusetts
Unresectable Breast Carcinoma clinical trials in Massachusetts
We’re tracking 26 recruiting unresectable breast carcinoma studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Boston, MassachusettsAges Any age - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Boston, MassachusettsAges 12 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT06507930Recruiting
Supporting advanced breast cancer patients at home on hospice
This study explores how to best support people with advanced breast cancer who are receiving hospice care at home. It includes short video or phone check-ins and a survey to learn about your experience.
Boston, MassachusettsAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Boston, MassachusettsAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Worcester, MassachusettsAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Boston, MassachusettsAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Boston, MassachusettsAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Boston, MassachusettsAges 12 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Boston, MassachusettsAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Boston, MassachusettsAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Boston, MassachusettsAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Boston, MassachusettsAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Boston, MassachusettsAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Boston, MassachusettsAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Boston, MassachusettsAges 18 years+
Unresectable Breast Carcinoma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting unresectable breast carcinoma studies listed above.
- Dana-Farber Cancer Institute · 16 studies
- Massachusetts General Hospital · 8 studies
- Beth Israel Deaconess Medical Center · 4 studies
- Boston Medical Center · 3 studies
- Brigham and Women's Hospital · 2 studies
- Tufts Medical Center · 2 studies
- Baystate Medical Center
- Research Site
What taking part in a unresectable breast carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there unresectable breast carcinoma clinical trials in Massachusetts?
- Yes. We're currently tracking 26 recruiting unresectable breast carcinoma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a unresectable breast carcinoma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a unresectable breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New unresectable breast carcinoma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.